FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189046973> ?p ?o ?g. }

• W3189046973 endingPage "2311" @default.
• W3189046973 startingPage "2302" @default.
• W3189046973 abstract "To examine whether glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are preferentially initiated among patients with cardiovascular disease, heart failure (HF), or nephropathy, where these drug classes have established benefit, compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), for which corresponding benefits have not been demonstrated.We retrospectively analyzed claims of adults with type 2 diabetes included in OptumLabs Data Warehouse, a deidentified database of commercially insured and Medicare Advantage beneficiaries, who first started GLP-1RA, SGLT2i, or DPP-4i therapy between 2016 and 2019. Using multinomial logistic regression, we examined the relative risk ratios (RRR) of starting GLP-1RA and SGLT2i compared with DPP-4i for those with a history of myocardial infarction (MI), cerebrovascular disease, HF, and nephropathy after adjusting for demographic and other clinical factors.We identified 75,395 patients who started GLP-1RA, 58,234 who started SGLT2i, and 91,884 who started DPP-4i. Patients with prior MI, cerebrovascular disease, or nephropathy were less likely to start GLP-1RA rather than DPP-4i compared with patients without these conditions (RRR 0.83 [95% CI 0.78-0.88] for MI, RRR 0.77 [0.74-0.81] for cerebrovascular disease, and RRR 0.87 [0.84-0.91] for nephropathy). Patients with HF or nephropathy were less likely to start SGLT2i (RRR 0.83 [0.80-0.87] for HF and RRR 0.57 [0.55-0.60] for nephropathy). Both medication classes were less likely to be started by non-White and older patients.Patients with cardiovascular disease, HF, and nephropathy, for whom evidence suggests a greater likelihood of benefiting from GLP-1RA and/or SGLT2i therapy, were less likely to start these drugs. Addressing this treatment/benefit paradox, which was most pronounced in non-White and older patients, may help reduce the morbidity associated with these conditions." @default.
• W3189046973 created "2021-08-16" @default.
• W3189046973 creator A5001881870 @default.
• W3189046973 creator A5031832642 @default.
• W3189046973 creator A5041424888 @default.
• W3189046973 creator A5061691563 @default.
• W3189046973 creator A5063962159 @default.
• W3189046973 creator A5068750234 @default.
• W3189046973 date "2021-08-04" @default.
• W3189046973 modified "2023-10-17" @default.
• W3189046973 title "Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities" @default.
• W3189046973 cites W2004670370 @default.
• W3189046973 cites W2022097092 @default.
• W3189046973 cites W2049877040 @default.
• W3189046973 cites W2114598208 @default.
• W3189046973 cites W2114794635 @default.
• W3189046973 cites W2126919962 @default.
• W3189046973 cites W2150959326 @default.
• W3189046973 cites W2170824629 @default.
• W3189046973 cites W2215377840 @default.
• W3189046973 cites W2306356166 @default.
• W3189046973 cites W2333798253 @default.
• W3189046973 cites W2339680651 @default.
• W3189046973 cites W2345117589 @default.
• W3189046973 cites W2345328813 @default.
• W3189046973 cites W2397301743 @default.
• W3189046973 cites W2413163057 @default.
• W3189046973 cites W2475954707 @default.
• W3189046973 cites W2560598095 @default.
• W3189046973 cites W2591385393 @default.
• W3189046973 cites W2616952314 @default.
• W3189046973 cites W2767197971 @default.
• W3189046973 cites W2800427972 @default.
• W3189046973 cites W2915807915 @default.
• W3189046973 cites W2921012991 @default.
• W3189046973 cites W2967214797 @default.
• W3189046973 cites W2968633786 @default.
• W3189046973 cites W2985116134 @default.
• W3189046973 cites W3007546177 @default.
• W3189046973 cites W3047536039 @default.
• W3189046973 cites W3092065440 @default.
• W3189046973 cites W3128844793 @default.
• W3189046973 cites W3172996796 @default.
• W3189046973 cites W4214911496 @default.
• W3189046973 cites W4246340431 @default.
• W3189046973 doi "https://doi.org/10.2337/dc20-2977" @default.
• W3189046973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34348996" @default.
• W3189046973 hasPublicationYear "2021" @default.
• W3189046973 type Work @default.
• W3189046973 sameAs 3189046973 @default.
• W3189046973 citedByCount "22" @default.
• W3189046973 countsByYear W31890469732022 @default.
• W3189046973 countsByYear W31890469732023 @default.
• W3189046973 crossrefType "journal-article" @default.
• W3189046973 hasAuthorship W3189046973A5001881870 @default.
• W3189046973 hasAuthorship W3189046973A5031832642 @default.
• W3189046973 hasAuthorship W3189046973A5041424888 @default.
• W3189046973 hasAuthorship W3189046973A5061691563 @default.
• W3189046973 hasAuthorship W3189046973A5063962159 @default.
• W3189046973 hasAuthorship W3189046973A5068750234 @default.
• W3189046973 hasBestOaLocation W31890469731 @default.
• W3189046973 hasConcept C126322002 @default.
• W3189046973 hasConcept C134018914 @default.
• W3189046973 hasConcept C2777180221 @default.
• W3189046973 hasConcept C2778198053 @default.
• W3189046973 hasConcept C2778653478 @default.
• W3189046973 hasConcept C2779922275 @default.
• W3189046973 hasConcept C2781184683 @default.
• W3189046973 hasConcept C44249647 @default.
• W3189046973 hasConcept C500558357 @default.
• W3189046973 hasConcept C555293320 @default.
• W3189046973 hasConcept C71924100 @default.
• W3189046973 hasConcept C82789193 @default.
• W3189046973 hasConceptScore W3189046973C126322002 @default.
• W3189046973 hasConceptScore W3189046973C134018914 @default.
• W3189046973 hasConceptScore W3189046973C2777180221 @default.
• W3189046973 hasConceptScore W3189046973C2778198053 @default.
• W3189046973 hasConceptScore W3189046973C2778653478 @default.
• W3189046973 hasConceptScore W3189046973C2779922275 @default.
• W3189046973 hasConceptScore W3189046973C2781184683 @default.
• W3189046973 hasConceptScore W3189046973C44249647 @default.
• W3189046973 hasConceptScore W3189046973C500558357 @default.
• W3189046973 hasConceptScore W3189046973C555293320 @default.
• W3189046973 hasConceptScore W3189046973C71924100 @default.
• W3189046973 hasConceptScore W3189046973C82789193 @default.
• W3189046973 hasIssue "10" @default.
• W3189046973 hasLocation W31890469731 @default.
• W3189046973 hasLocation W31890469732 @default.
• W3189046973 hasLocation W31890469733 @default.
• W3189046973 hasLocation W31890469734 @default.
• W3189046973 hasLocation W31890469735 @default.
• W3189046973 hasOpenAccess W3189046973 @default.
• W3189046973 hasPrimaryLocation W31890469731 @default.
• W3189046973 hasRelatedWork W1971350538 @default.
• W3189046973 hasRelatedWork W1974938188 @default.
• W3189046973 hasRelatedWork W2353977361 @default.
• W3189046973 hasRelatedWork W2361969416 @default.
• W3189046973 hasRelatedWork W2382058954 @default.

• next